AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26268362 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE (Creating Opportunities for Personal Empowerment) online cognitive-behavioral skill-building program
Number of subjects: 121
Study 26268362 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 121
Study 23529166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target BP <130/80 mm Hg)
Number of subjects: 37
Study 23529166 — intervention group
Group type: COMPARATOR
Intervention: Usual blood pressure lowering (target BP <140/85 mm Hg)
Number of subjects: 37
Study 21166600 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg once daily in the morning
Number of subjects: 34
Study 21166600 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg once daily in the evening
Number of subjects: 34
Study 21166600 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg twice daily
Number of subjects: 34
Study 19877092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (60 minutes, 10 modified forms from classic Yang style, twice weekly for 12 weeks)
Number of subjects: 40
Study 19877092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 40
Study 16503464 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine
Number of subjects: 1136
Study 16503464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study 15566706 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step protocol
Number of subjects: 20
Study 15566706 — intervention group
Group type: COMPARATOR
Intervention: One-step protocol
Number of subjects: 20
Study 15566706 — intervention group
Group type: COMPARATOR
Intervention: Three-step protocol
Number of subjects: 20
Study 11296615 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg) administered on days carboplatin was given
Number of subjects: 28
Study 11296615 — intervention group
Group type: COMPARATOR
Intervention: Control group (RCT alone)
Number of subjects: 28
Study 11296615 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 28
Study 9290304 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for lymphoedema
Number of subjects: 34
Study 8489055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with 70% N2O
Number of subjects: 0
Study 3103174 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.42% carbonated bupivacaine
Number of subjects: 62
Study 3103174 — intervention group
Group type: COMPARATOR
Intervention: 20 ml 0.5% bupivacaine hydrochloride
Number of subjects: 62
Study 29398871 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS
Number of subjects: 42
Study 29398871 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 26706193 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM-guided only ablation
Number of subjects: 29
Study 24815098 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote follow-up (low-sensitivity pregnancy test and standardized symptom questionnaire via online, text message, or telephone)
Number of subjects: 999
Study 24815098 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote follow-up (text message)
Number of subjects: 999
Study 24815098 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote follow-up (telephone)
Number of subjects: 999
Study 24815098 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote follow-up (online)
Number of subjects: 999
Study 24815098 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based follow-up
Number of subjects: 999
Study 24815098 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote follow-up
Number of subjects: 999
Study 24815098 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptability of follow-up methods
Number of subjects: 999
Study 22438072 — intervention group
Group type: EXPERIMENTAL
Intervention: Densulin® N (NPH) plus Densulin® R (regular), 100 UI/ml
Number of subjects: 12
Study 22438072 — intervention group
Group type: COMPARATOR
Intervention: InsulatardHM® (NPH) plus ActrapidHM®, 100 UI/ml
Number of subjects: 12
Study 20133824 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic factors influencing default-mode functional connectivity
Number of subjects: 333
Study 20133824 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroanatomic variation in the default-mode network
Number of subjects: 333
Study 20133824 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic correlations between regions within the default-mode network
Number of subjects: 333
Study 20133824 — intervention group
Group type: EXPERIMENTAL
Intervention: Subnetwork formation within the default-mode network
Number of subjects: 333
Study 20133824 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishing heritability of default-mode functional connectivity
Number of subjects: 333
Study 18559720 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 6632
Study 18559720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6632
Study 15789231 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac bone graft (IBG) bilaterally in group A
Number of subjects: 57
Study 15789231 — intervention group
Group type: EXPERIMENTAL
Intervention: IBG on the left side and coralline hydroxyapatite (CH) mixed with local bone and bone marrow on the right side in group B
Number of subjects: 57
Study 15789231 — intervention group
Group type: EXPERIMENTAL
Intervention: Coralline hydroxyapatite (CH) mixed with local bone and bone marrow bilaterally in group C
Number of subjects: 57
Study 15789231 — intervention group
Group type: COMPARATOR
Intervention: Coralline hydroxyapatite (CH)
Number of subjects: 57
Study 15789231 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 57
Study 12208797 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/d transdermal E2
Number of subjects: 189
Study 12208797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d oral CEE
Number of subjects: 189
Study 12208797 — intervention group
Group type: COMPARATOR
Intervention: fenretinide
Number of subjects: 189
Study 12208797 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 189
Study 12080685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg in 10 ml solution
Number of subjects: 60
Study 12080685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NS 10 ml)
Number of subjects: 60
Study 7482738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HCV positive recipients
Number of subjects: 103
Study 1773686 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation intervention (45-min intervention + 1-h self-administered booster)
Number of subjects: 0
Study 1773686 — intervention group
Group type: COMPARATOR
Intervention: Control group (comprehensive 3-day evaluation and educational program)
Number of subjects: 0
Study 1773686 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation intervention
Number of subjects: 0
Study 1773686 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 6423870 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole combined with Mitomycin‐C, FT‐207 and PS‐K
Number of subjects: 0
Study 6423870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Levamisole)
Number of subjects: 0
Study 6423870 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study 31697218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Motivational Interviewing (IMI), 9-session counseling intervention
Number of subjects: 215
Study 31697218 — intervention group
Group type: COMPARATOR
Intervention: Standard single session of Motivational Interviewing (SMI) with attention control (nutritional education)
Number of subjects: 215
Study 30488367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive treatment (CIST) including intravenous cyclophosphamide, mycophenolate mofetil, azathioprine, leflunomide, hydroxychloroquine, and glucocorticoids.
Number of subjects: 191
Study 30488367 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (CYC) alone with glucocorticoids.
Number of subjects: 191
Study 27893167 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs laser 815 nm wavelength, 1 W output power, continuous emissions, 4 s, 4 J, fluence rate 133·3 J cm‐2
Number of subjects: 44
Study 27893167 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAlAs infrared laser, 815 nm wavelength, 1 W output power, continuous emissions, 6 s, 6 J, fluence rate 200 J cm‐2
Number of subjects: 44
Study 27893167 — intervention group
Group type: COMPARATOR
Intervention: Placebo group, sham laser
Number of subjects: 44
Study 27311900 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital outreach intervention programme for disease management (3-month hospital-based pulmonary rehabilitation followed by a home-based programme)
Number of subjects: 220
Study 27311900 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge care (control group)
Number of subjects: 220
Study 27311900 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital outreach intervention programme for disease management
Number of subjects: 220
Study 24842445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg or 30 mg total dose)
Number of subjects: 64
Study 24842445 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 64
Study 22586589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 15
Study 22586589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20032533 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz with concomitant rifampicin
Number of subjects: 0
Study 20032533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine with concomitant rifampicin
Number of subjects: 0
Study 20032533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted protease inhibitors with rifampicin
Number of subjects: 0
Study 20032533 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose protease inhibitors with rifampicin
Number of subjects: 0
Study 20032533 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin instead of rifampicin
Number of subjects: 0
Study 17364581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia at 8000 feet
Number of subjects: 14
Study 17364581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia at 12000 feet
Number of subjects: 14
Study 17364581 — intervention group
Group type: COMPARATOR
Intervention: Control (normoxia)
Number of subjects: 14
Study 14974750 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 dollar cash incentive
Number of subjects: 119
Study 14974750 — intervention group
Group type: COMPARATOR
Intervention: 5 dollar non-cash incentive
Number of subjects: 119
Study 11794812 — intervention group
Group type: EXPERIMENTAL
Intervention: New design of tablets with a hydrophilic matrix containing 300 mg of diltiazem
Number of subjects: 12
Study 11794812 — intervention group
Group type: COMPARATOR
Intervention: Capsules containing prolonged liberation microgranules of 300 mg of diltiazem (reference formulation)
Number of subjects: 12
Study 10189261 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbatrol (CBTL) 400 mg b.i.d. for 5 days
Number of subjects: 15
Study 10189261 — intervention group
Group type: COMPARATOR
Intervention: Tegretol-XR (TXR) 400 mg b.i.d. for 5 days
Number of subjects: 15
Study 7632207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 77
Study 7632207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 77
Study 3052572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase added to lignocaine with adrenaline
Number of subjects: 0
Study 3052572 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine with adrenaline without hyaluronidase (Control)
Number of subjects: 0
Study 29613940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin with positive verbal suggestions
Number of subjects: 108
Study 29613940 — intervention group
Group type: COMPARATOR
Intervention: Placebo with positive verbal suggestions
Number of subjects: 108
Study 29613940 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin without suggestions
Number of subjects: 108
Study 29613940 — intervention group
Group type: COMPARATOR
Intervention: Placebo without suggestions
Number of subjects: 108
Study 28471208 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 240
Study 28471208 — intervention group
Group type: COMPARATOR
Intervention: Literature control
Number of subjects: 240
Study 26442442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov external fixator with arthroscopy (Group B)
Number of subjects: 23
Study 26442442 — intervention group
Group type: COMPARATOR
Intervention: Ilizarov external fixator without arthroscopy (Group A)
Number of subjects: 23
Study 24349363 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1-based chemotherapy
Number of subjects: 821
Study 24349363 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine-based chemotherapy
Number of subjects: 821
Study 20854173 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed antiretroviral therapy (DOT)
Number of subjects: 77
Study 20854173 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 77
Study 18349204 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 20
Study 18349204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcitonin (200 IE) and ketamine (0.4 mg/kg)
Number of subjects: 20
Study 18349204 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 200 IE
Number of subjects: 20
Study 18349204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 20
Study 18349204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcitonin and ketamine
Number of subjects: 20
Study 17066247 — intervention group
Group type: EXPERIMENTAL
Intervention: MARB regimen (metronidazole 250 mg tid + amoxicillin 500 mg qid + ranitidine 300 mg hs + bismuth 300 mg qid) for 14 days
Number of subjects: 75
Study 17066247 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA regimen (omeprazole 40 mg bid + clarithromycin 500 mg bid + amoxicillin 1 g bid) for 14 days
Number of subjects: 75
Study 15068414 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone (150 mg/day)
Number of subjects: 68
Study 15068414 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonist (nizatidine, 300 mg/day)
Number of subjects: 68
Study 15068414 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (3 g/day)
Number of subjects: 68
Study 15068414 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone (in vitro)
Number of subjects: 68
Study 11302295 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial therapy (11 individual sessions including physiologic relaxation, cognitive behavioral therapy, and cardiovascular health education)
Number of subjects: 129
Study 11302295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychosocial therapy)
Number of subjects: 129
Study 11302295 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial therapy
Number of subjects: 129
Study 9350935 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral right atrial location
Number of subjects: 28
Study 9350935 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferomedial right atrial location
Number of subjects: 28
Study 9350935 — intervention group
Group type: EXPERIMENTAL
Intervention: High right atrial appendage location
Number of subjects: 28
Study 9350935 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation thresholds for high right atrial appendage
Number of subjects: 28
Study 9350935 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation thresholds for anterolateral right atrium
Number of subjects: 28
Study 9350935 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation thresholds for inferomedial right atrium
Number of subjects: 28
Study 9350935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain perception and tolerability
Number of subjects: 28
Study 8507888 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant alpha‐2a interferon at doses of 3MU intramuscularly thrice weekly for 6 months
Number of subjects: 56
Study 8507888 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 56
Study 3318740 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 65
Study 3318740 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of ventilation (double-lumen endobronchial tube and collapse of one lung)
Number of subjects: 65
Study 29352014 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive social support interventions
Number of subjects: 201
Study 29352014 — intervention group
Group type: COMPARATOR
Intervention: Health education alone
Number of subjects: 201
Study 28318938 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐month nurse case manager (NCM) intervention
Number of subjects: 140
Study 28318938 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 140
Study 25768064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate-intensity combined endurance and resistance training for 24 weeks
Number of subjects: 44
Study 25768064 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group
Number of subjects: 44
Study 22995766 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (abstinence) at Year 3 follow-up
Number of subjects: 1504
Study 22995766 — intervention group
Group type: COMPARATOR
Intervention: Continuing to smoke at Year 3 follow-up
Number of subjects: 1504
Study 19874638 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphora patients (nasolacrimal duct obstruction)
Number of subjects: 18
Study 19874638 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy nasal cavities of patients with unilateral epiphora
Number of subjects: 18
Study 19874638 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 18
Study 18250970 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBCT) - 15 daily visits, 2-3 minutes each at temperatures from -160°C to -110°C
Number of subjects: 60
Study 18250970 — intervention group
Group type: COMPARATOR
Intervention: Standard psychopharmacotherapy (Control)
Number of subjects: 60
Study 15990241 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat sweets for alcohol urges
Number of subjects: 68
Study 15990241 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat a balanced diet
Number of subjects: 68
Study 15990241 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoid sweets
Number of subjects: 68
Study 15990241 — intervention group
Group type: COMPARATOR
Intervention: Light-drinking controls (C's)
Number of subjects: 68
Study 15990241 — intervention group
Group type: EXPERIMENTAL
Intervention: AD subjects who remained abstinent for 6 months
Number of subjects: 68
Study 12851604 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 16949
Study 12851604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 16949
Study 12851604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (after 4 hours of symptom-onset)
Number of subjects: 16949
Study 12851604 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (after 4 hours of symptom-onset)
Number of subjects: 16949
Study 10048685 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vitamin A concentration
Number of subjects: 207
Study 10048685 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of change in vitamin A concentrations
Number of subjects: 207
Study 10048685 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vitamin A concentration and rate of change
Number of subjects: 207
Study 8886215 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan 500 mg once daily
Number of subjects: 42
Study 8886215 — intervention group
Group type: COMPARATOR
Intervention: Naprosyn 500 mg BID
Number of subjects: 42
Study 8886215 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprelan 1000 mg once daily
Number of subjects: 42
Study 8886215 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg QID
Number of subjects: 42
Study 1793782 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral mesalazine four times daily (18 patients)
Number of subjects: 37
Study 1793782 — intervention group
Group type: COMPARATOR
Intervention: Steroid enemas twice daily (19 patients)
Number of subjects: 37
Study 6099756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 407
Study 6099756 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (multiple doses)
Number of subjects: 407
Study 30615259 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple low CNI regimen (everolimus target trough level 3-5 ng/mL, reduced CNI with tacrolimus 3-5 ng/mL or cyclosporine 25-75 ng/mL, cell cycle inhibitor, prednisone)
Number of subjects: 130
Study 30615259 — intervention group
Group type: COMPARATOR
Intervention: Standard triple CNI regimen (tacrolimus target trough level >5 ng/mL or cyclosporine >100 ng/mL, cell cycle inhibitor, prednisone)
Number of subjects: 130
Study 29192293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MI (no manipulation after milling)
Number of subjects: 20
Study 29192293 — intervention group
Group type: EXPERIMENTAL
Intervention: Group FG (oven fired-glazing after milling)
Number of subjects: 20
Study 26980942 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mild traumatic brain injury (MTBI)
Number of subjects: 151
Study 25099464 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy dietary supplement (isoflavone 90mg)
Number of subjects: 60
Study 25099464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (estradiol 1 mg plus noretisterone 0.5 mg)
Number of subjects: 60
Study 25099464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22285123 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion (500 mL of dextrose in water (DW) 10% + 40 U of regular insulin + 40 mEq of KCl, and 2 g of MgSO(4)) at a rate of 1 mL/kg/h for 10 hours preoperatively and until the removal of the aortic cross‐clamp
Number of subjects: 66